Company intelligence / Profile preview
PMV Pharmaceuticals, Inc.
Princeton, New Jersey, United Statespmvpharma.com ↗
- Ownership
- Public · PMVP
- Development stage
- Phase 2
01
Overview
PMV's lead candidate rezatapopt (PC14586) is in Phase 2 pivotal trials for patients with TP53 Y220C and KRAS wild-type advanced solid tumors. Enrollment is on track with more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific. Interim analysis data is expected mid-2025. A Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with relapsed/refractory AML/MDS harboring a TP53 Y220C mutation has also commenced enrollment.[5][6]
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Merck & Co. (for combination with Keytruda)Foundation MedicineMD Anderson Cancer Center
04
Financials
- Market cap
- $68M
- Total revenue
- $0
- Enterprise value
- $-11.2M
Beyond the preview
Go deeper on PMV Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMV Pharmaceuticals, Inc..